JP2005508162A - Ａｐｏ−２リガンド変異体とその使用法 - Google Patents

Ａｐｏ−２リガンド変異体とその使用法 Download PDF

Info

Publication number
JP2005508162A
JP2005508162A JP2003532638A JP2003532638A JP2005508162A JP 2005508162 A JP2005508162 A JP 2005508162A JP 2003532638 A JP2003532638 A JP 2003532638A JP 2003532638 A JP2003532638 A JP 2003532638A JP 2005508162 A JP2005508162 A JP 2005508162A
Authority
JP
Japan
Prior art keywords
apo
ligand
polypeptide
variant polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003532638A
Other languages
English (en)
Japanese (ja)
Inventor
ロバート エフ． ケリー，
ステファニー エイチ． リンドストロム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2005508162A publication Critical patent/JP2005508162A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2003532638A 2001-10-02 2002-10-01 Ａｐｏ−２リガンド変異体とその使用法 Pending JP2005508162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32662201P 2001-10-02 2001-10-02
PCT/US2002/031210 WO2003029420A2 (en) 2001-10-02 2002-10-01 Apo-2 ligand variants and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007211072A Division JP4603023B2 (ja) 2001-10-02 2007-08-13 Ａｐｏ−２リガンド変異体とその使用法

Publications (1)

Publication Number Publication Date
JP2005508162A true JP2005508162A (ja) 2005-03-31

Family

ID=23272996

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003532638A Pending JP2005508162A (ja) 2001-10-02 2002-10-01 Ａｐｏ−２リガンド変異体とその使用法
JP2007211072A Expired - Lifetime JP4603023B2 (ja) 2001-10-02 2007-08-13 Ａｐｏ−２リガンド変異体とその使用法
JP2010120168A Pending JP2010220623A (ja) 2001-10-02 2010-05-26 Ａｐｏ−２リガンド変異体とその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007211072A Expired - Lifetime JP4603023B2 (ja) 2001-10-02 2007-08-13 Ａｐｏ−２リガンド変異体とその使用法
JP2010120168A Pending JP2010220623A (ja) 2001-10-02 2010-05-26 Ａｐｏ−２リガンド変異体とその使用法

Country Status (6)

Country Link
US (3) US20040186051A1 (de)
EP (2) EP1501866A4 (de)
JP (3) JP2005508162A (de)
CA (1) CA2461292A1 (de)
IL (3) IL161051A0 (de)
WO (1) WO2003029420A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532048A (ja) * 2006-04-07 2009-09-10 ノボ ノルディスク ヘルス ケア アーゲー Ｖｉｉ因子・組織因子共有結合複合体
JP2015533838A (ja) * 2012-10-25 2015-11-26 ジェジャン・ユニバーシティー ｒＴＲＡＩＬ突然変異体およびそのモノメチルアウリスタチンＥコンジュゲート

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
DK1450847T3 (da) * 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
JP4574350B2 (ja) * 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
CA2577823A1 (en) * 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
CN103534273B (zh) * 2011-09-16 2020-05-12 北京沙东生物技术有限公司 环化变构trail/apo2l及其编码基因与应用
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
WO2015168468A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
DK3389696T3 (da) 2015-12-17 2024-12-16 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
WO2021194913A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JPH06500559A (ja) 1990-08-17 1994-01-20 ジェネンテク，インコーポレイテッド 金属イオン媒介のポリペプチドホルモンのレセプター結合
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JPH08506095A (ja) 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
CA2160154A1 (en) 1993-04-07 1994-10-13 George N. Cox Methods of using insulin-like growth factor binding proteins
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
CA2230492C (en) * 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU713471C (en) 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US7803615B1 (en) 1997-03-17 2010-09-28 Human Genome Sciences, Inc. Death domain containing receptor 5
HU230547B1 (hu) 1997-04-16 2016-11-28 Amgen Inc. Osteoprotegerin-kötő fehérjék és receptorok
CA2287085A1 (en) 1997-04-16 1998-10-22 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
EP2083079A1 (de) 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
DE69841176D1 (en) 1997-08-26 2009-11-05 Genentech Inc Rtd receptor
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ES2316182T3 (es) 1998-01-15 2009-04-01 Genentech, Inc. Ligando apo-2.
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック， インコーポレイテッド 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法
AU766984B2 (en) 1999-09-30 2003-10-30 Trustees Of The University Of Pennsylvania, The Trail: an inhibitor of autoimmune inflammation and cell cycle progression
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
JP4574350B2 (ja) * 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532048A (ja) * 2006-04-07 2009-09-10 ノボ ノルディスク ヘルス ケア アーゲー Ｖｉｉ因子・組織因子共有結合複合体
JP2015533838A (ja) * 2012-10-25 2015-11-26 ジェジャン・ユニバーシティー ｒＴＲＡＩＬ突然変異体およびそのモノメチルアウリスタチンＥコンジュゲート

Also Published As

Publication number Publication date
EP1501866A2 (de) 2005-02-02
EP2348043A1 (de) 2011-07-27
IL211772A0 (en) 2011-05-31
US20040186051A1 (en) 2004-09-23
IL161051A0 (en) 2004-08-31
JP4603023B2 (ja) 2010-12-22
WO2003029420A2 (en) 2003-04-10
US20090137476A1 (en) 2009-05-28
JP2008043335A (ja) 2008-02-28
IL161051A (en) 2011-07-31
EP1501866A4 (de) 2006-02-08
US20130108578A1 (en) 2013-05-02
WO2003029420A3 (en) 2004-11-04
CA2461292A1 (en) 2003-04-10
JP2010220623A (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
JP4603023B2 (ja) Ａｐｏ−２リガンド変異体とその使用法
JP4574350B2 (ja) Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
KR100674528B1 (ko) 2가 금속 이온을 사용한 Ａｐｏ-2 리간드 제조 방법
JP2013060471A (ja) 低温での結晶化を使用して、Ａｐｏ２リガンド／ＴＲＡＩＬを精製するための方法
AU2007201621A1 (en) Apo-2 ligand variants and uses thereof
AU2002330173A1 (en) Apo-2 ligand variants and uses thereof
AU2011235952A1 (en) APO-2 ligand variants and uses thereof
HK1113382B (en) Method of purifying apo-2 ligand/trail using crystallisation in the cold

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090526